Diagnostic Discussions: Real-World Cases on the Identification of Ocular Surface Diseases (CE Webcast)
Activity Description and Purpose
Corneal nerves have an essential role in maintaining ocular surface health and homeostasis. Manifestations of neurosensory abnormalities affecting corneal innervation include dry eye disease and neurotrophic keratopathy. These conditions can exist as a standalone entity, but they can also be concurrent and have overlapping features, making diagnosis challenging. Early diagnosis is important to allow intervention that can help to restore function and improve quality of life. This educational activity includes real-world cases and discussion on diagnostic modalities used to identify these conditions and options for treatment. The desired results of this educational activity are to familiarize optometrists with the role of the corneal nerve in maintaining ocular surface homeostasis and practical strategies for screening and diagnosing of ocular surface disease that can arise as the result of corneal nerve dysfunction.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Review diagnostic modalities used for proper assessment of ocular surface disease
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
|Douglas K. Devries, OD (Co-Chair)|
Associate Clinical Professor
Pacific University College of Optometry
Advanced Vision and Laser Center
|Kendall E. Donaldson, MD, MS (Co-Chair)|
Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute in Plantation
Pedram Hamrah, MD
|Nathan Lighthizer, OD|
Associate Dean and Associate Professor
Chief, Specialty Care Clinics
Northeastern State University College of Optometry
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company. All relevant relationships with ineligible companies have been mitigated.
Douglas K. Devries, OD, is a consultant for Alcon, Allergan, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, and Visus Therapeutics; and is on the speakers bureau for Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Kendall E. Donaldson, MD, MS, is a consultant for AcuFocus, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Omeros Corporation, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Zeiss.
Pedram Hamrah, MD, is a consultant for Kala Pharmaceuticals and Santen Inc; is an advisory board member of Dompé US, Inc, Hawkeye Therapeutics, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, and Oyster Point Pharma, Inc; and is a contracted researcher for Claris Biotherapeutics, CooperVision, Dompé US, Inc, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, Ocular Therapeutix, Inc, OKYO Pharma, Limited, and Oyster Point Pharma, Inc.
Nathan Lighthizer, OD, is a consultant for Diopsys, Inc, and OCuSOFT; is an advisory board member of Bruder Healthcare, EyePromise, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, and Sight Sciences; and is on the speakers bureau for Dompé US, Inc, Ellex, and Sun Pharmaceutical Industries, Inc.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE accredited for 1.0 CE credit for optometrists.
COPE Course ID: 87352-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
This activity, COPE Activity Number 126954, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 266.4
- 1.00 COPE